3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
INmune Bio's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 23.05%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for INmune Bio's 3-Year ROIIC % or its related term are showing as below:
INMB's 3-Year ROIIC % is ranked better than 66.01% of 1324
companies
in the Biotechnology industry
Industry Median: -4.42
vs INMB: 23.05
INmune Bio (NAS:INMB) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
INmune Bio 3-Year ROIIC % Related Terms
INmune Bio 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for INmune Bio's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INMB vs GRCE, NTRB, ABVC: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, INmune Bio's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where INmune Bio's 3-Year ROIIC % falls into.
INmune Bio's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -30.869 (Dec. 2025) - -25.951 (Dec. 2022) )
/
( 3.087 (Dec. 2025) - 24.427 (Dec. 2022) )
=
-4.918
/
-21.34
=
23.05%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
INmune Bio (INMB) has a 3-Year ROIIC % of 23.05 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #450 out of 1324 companies in the Biotechnology industry, placing it in the top 34%.
Is INmune Bio's 3-Year ROIIC % too high?
INmune Bio's current 3-Year ROIIC % is 23.05. Based on the distribution chart, INmune Bio ranks #450 out of 1324 companies in the Biotechnology industry, which is above the industry midpoint. Overall, INmune Bio has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's 3-Year ROIIC % compare to GRCE and NTRB?
According to the Biotechnology industry distribution chart, INmune Bio ranks #450 out of 1324 companies for 3-Year ROIIC %. This puts INmune Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on INmune Bio and its competitors. INmune Bio's current 3-Year ROIIC % is 23.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Fairly Valued. The stock's GF Value™ is $1.82, compared to a current price of $1.70 — trading 6.6% below its estimated fair value. The current 3-Year ROIIC % is 23.05. INmune Bio's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For INmune Bio (INMB), the current 3-Year ROIIC % is 23.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued.
The current stock price of $1.70 is trading 6.6% below its estimated GF Value™ of $1.82.
GuruFocus considers INmune Bio to be Fairly Valued.
Key valuation signals for INMB:
3-Year ROIIC %: 23.05
GF Value™: $1.82 vs. price of $1.70 (6.6% below fair value)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
57GF Score
Get the complete analysis for INMB
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
